On 9 June 2021 from 14:00 - 15:30 hrs CEST, the Innovative Medicines Initiative (IMI) will organize an ‘Impact on data’ event. HARMONY Partner Lars Bullinger of Charité Berlin will represent the HARMONY Alliance at this virtual meeting.
IMI has had big data projects since its creation. These projects are applying big data to advance research in the fields of hematological malignancies, cardiovascular disease, Alzheimer’s disease, and prostate cancer. IMI is now organizing a series of live sessions on IMI impact, where key actors will explore the challenges and demonstrate how IMI contributed. In addition, patients’ testimonies will be shared.
Professor Lars Bullinger will give a presentation at this event about the HARMONY Big Data Platform - using big data to gather, integrate and analyse anonymous patient data from a number of high-quality sources in order to define clinical endpoints and outcomes for blood cancer patients. Prof. Bullinger is an expert in Acute Myeloid Leukemia and leading HARMONY Work Package Definitions of Outcomes. View all HARMONY Research Projects.
#BigDataforbloodcancer | Big Data accelerate better and faster treatment for Patients with Hematologic Malignancies
The HARMONY Alliance is a European Public–Private Partnership for Big Data in Hematology that is capturing and mining Big Data on Hematologic Malignancies. Both projects of the HARMONY Alliance, HARMONY and HARMONY PLUS, are funded by the Innovatie Medicines Initiative (IMI).
HARMONY unites more than 100 organizations such as European medical associations, hospitals, research institutes, patient organizations, pharmaceutical and IT companies. HARMONY uses Big Data analytics to accelerate the development of more effective treatments for blood cancer patients. Data are stored in HARMONY’s Big Data Platform, which has already identified over 70,000 anonymized patient records, making it one of the largest databases of its kind. Leading research teams are currently using this wealth of information to answer critical questions about hematologic malignancies that cannot be addressed with other methods.
Join the HARMONY Alliance: watch the video and/or contact us now >
See what other meetings HARMONY is holding and attending by visiting our meetings page. >
Receive the latest news. Click here to subscribe!
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
